Prelude Therapeutics Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. The filing was signed November 12, 2021. Prelude is a clinical-stage precision oncology company; it has no approved products and has generated no revenue.
Financial performance and liquidity
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $22.7 million | $61.6 million |
| General and administrative expense | $8.1 million | $19.1 million |
| Total operating expenses | $30.8 million | $80.7 million |
| Net loss | $30.7 million | $78.9 million |
| Net loss per share, basic and diluted | $0.66 | $1.72 |
| Cash used in operating activities | Not provided for quarter | $57.8 million |
- At September 30, cash and cash equivalents were $61.4 million and marketable securities were $259.4 million, totaling $320.9 million. Current assets were $325.9 million; current liabilities were $19.7 million.
- Cash and cash equivalents fell from $218.3 million at December 31, 2020, largely reflecting $260.0 million of marketable-security purchases, not solely operating cash burn. Investing cash outflow was $262.0 million; financing provided $162.9 million, including $161.4 million net proceeds from a January 2021 stock offering.
- Accumulated deficit was $186.3 million. The company reported no debt or credit facility; lease liabilities totaled $2.1 million. Profit margins are not meaningful given the absence of revenue.
Changes versus prior comparable periods
- Q3 operating expenses rose $12.7 million year over year, with R&D up $7.4 million and G&A up $5.3 million. Management attributed increases to clinical and discovery-program activity, higher personnel costs, professional fees, and public-company costs.
- Q3 net loss increased to $30.7 million from $16.8 million. For the first nine months, net loss increased to $78.9 million from $37.7 million.
- Nine-month operating cash use increased to $57.8 million from $31.3 million. Stock-based compensation rose to $15.2 million from $2.5 million for the nine-month period.
- Reported loss per share improved versus 2020, but weighted-average shares increased substantially following the 2020 IPO; the per-share comparison is therefore not directly indicative of improved underlying results.
- Q3 other income declined year over year, primarily because a Delaware R&D tax credit recognized in Q3 2020 was not received in Q3 2021.
Pipeline, outlook, and material developments
- PRT543: Phase 1 dose escalation included 49 patients at an August 6 data cutoff. The company reported target engagement and preliminary activity, including a durable complete response in an HRD-positive ovarian cancer patient and prolonged stable disease in five patients. Grade 3-or-higher treatment-related thrombocytopenia and anemia occurred in 27% and 12%, respectively. Biomarker-selected expansion enrollment was ongoing; expansion data were anticipated during 2022.
- PRT811: Phase 1 dose escalation included 45 patients at an August 13 cutoff, including 18 with high-grade gliomas. The company reported preliminary responses and stable disease, including additional post-cutoff observations it described as unconfirmed. Grade 3-or-higher treatment-related thrombocytopenia was 7%. Expansion enrollment was expected to begin in Q4 2021, with data anticipated during 2022.
- PRT1419: The oral formulation was in Phase 1 dose escalation for hematologic malignancies; an IV-formulation Phase 1 study in solid tumors was underway. PRT2527: The company said its IND had been cleared and a clinical trial was expected to begin by year-end 2021.
- Management said existing cash, cash equivalents, and marketable securities should fund operating expenses and capital expenditures into the second half of 2023. This estimate depends on assumptions that could prove inaccurate; additional funding will be needed thereafter, and no committed financing source was in place.
- Management expected R&D spending to rise as clinical programs advance and G&A spending to increase to support growth and public-company obligations. The filing cautions that early clinical findings are preliminary and may not predict later trial outcomes.
- COVID-19 had caused limited delays in some trial-site initiations, patient participation, and enrollment; management said lead programs and research remained on track, while warning that further disruption could delay trials and increase costs.
- After quarter-end, CFO Brian Piper announced his resignation effective November 19, 2021; Laurent Chardonnet was appointed CFO effective November 29. Chief Medical Officer David Mauro departed November 9; a successor search was ongoing, with board member Victor Sandor providing interim clinical-development oversight.
- In September 2021, Prelude entered a roughly one-year Darwin Health research collaboration, committing $3.0 million in research funding. Darwin Health may also receive development and regulatory milestones of up to $3.0 million per product candidate and low-single-digit royalties on qualifying net sales.
Key risks and contingencies
- Clinical and regulatory risk is substantial: lead candidates remain early-stage, efficacy and safety are unproven, and further trials, approvals, and commercialization are uncertain.
- Continued losses and dependence on future financing could require dilution, debt with restrictive terms, or licensing of valuable rights; inability to raise capital could force program delays or reductions.
- The company relies on CROs and third-party manufacturers, including sole-source suppliers for certain manufacturing components; supply, quality, or compliance issues could disrupt development.
- Other disclosed risks include competition, patient-enrollment challenges, adverse effects, intellectual-property disputes, and the potential for COVID-19-related disruption. Management reported no material legal proceeding and no material change in internal control over financial reporting during the quarter; disclosure controls were assessed as effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether the stated cash runway into the second half of 2023 remains supported by spending, trial timelines, and marketable-security liquidity.
- Updated, final clinical data for PRT543 and PRT811, including response durability, patient numbers, adverse events, and expansion-cohort results.
- Actual timing and progress of PRT1419 and PRT2527 studies, and whether COVID-19 or manufacturing constraints affect enrollment or milestones.
- Future operating cash use, stock-based compensation, equity dilution, and any financing or collaboration terms.
- Execution of the CFO transition, appointment of a permanent CMO, and the financial and commercial terms of the Darwin Health collaboration.